Copenhagen, April 17, 2018 – Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced the creation of a US subsidiary, based in Newton, Massachusetts. The subsidiary is named Orphazyme US, Inc., and will directly support the US market to establish closer relationships with the medical, patient, and financial communities as the company expands its development program and global reach. The company also announced that Paul Merrigan will head Orphazyme US, Inc. as the US President in addition to his responsibilities as Chief Commercial Officer.
“The opening of a subsidiary in the US is a significant step in Orphazyme’s strategy to increase our efforts in developing partnerships and building relationships with the key stakeholders of researchers, healthcare providers, and patient organizations within the largest healthcare market in the world, and gradually increase our connections with the investor community,” Anders Hinsby, CEO of Orphazyme, said, and also added, “we decided to put down our roots and grow our business in the greater Boston area because it is the cradle of the rare disease biopharmaceutical industry, its proximity to prestigious academic institutions, and its access to highly qualified talent”.
Paul Merrigan commented, “We are extremely excited to build a dedicated and experienced team in the US that will allow us to more deeply engage with the key stakeholders and communities who we plan to serve with the ultimate goal of bringing hope through our treatments to patients with serious and life-threatening rare diseases.”
“We welcome Orphazyme to the US and to the Boston/Cambridge corridor to join this vibrant landscape of other innovative companies who are focused on developing orphan drugs for patients in desperate need,” says Peter Saltonstall, President and CEO of the National Organization of Rare Disorders (NORD). “We look forward to working with the Orphazyme team to help get their orphan drugs currently in clinical development to the finish line of being accessible to patients.”